Assess whether regulatory approval is a timing risk or a deal risk (483133)

SITUATION Regulatory-approval critical-path calendar arrived with a CIM that omitted a material litigation for integration-risk PMO. That is a M&A Due Diligence Earnings and Revenue Quality decision on regulatory approval is a in a sponsor doing confirmatory after a tight auction.

DECISION Integration-risk PMO in a sponsor doing confirmatory after a tight auction must choose Regulatory approval is a timing risk / A deal risk using regulatory-approval critical-path calendar after a CIM that omitted a material litigation.

HYPOTHESES TO TEST 1. Regulatory-approval critical-path calendar reads as Regulatory approval is a timing risk once a CIM that omitted a material litigation is lined up to the same M&A Due Diligence population. 2. Regulatory-approval critical-path calendar is closer to A deal risk after a CIM that omitted a material litigation; Regulatory approval is a timing risk would over-claim this Earnings and Revenue Quality extract. 3. A dual reading is still live in regulatory-approval critical-path calendar for integration-risk PMO in a sponsor doing confirmatory after a tight auction. 4. Regulatory-approval critical-path calendar is missing the fact integration-risk PMO needs after a CIM that omitted a material litigation; stop this M&A Due Diligence close.

ANALYSIS REQUIRED 1. Test whether a CIM that omitted a material litigation is a diligence gap, a price chip, or a walk-away. 2. Separate a one-off add-back from a recurring earnings issue in regulatory-approval critical-path calendar. 3. Map reps, earnout mechanics, and integration risk a sponsor doing confirmatory after a tight auction would inherit. 4. For this M&A Due Diligence Earnings and Revenue Quality file, read regulatory-approval critical-path calendar against a CIM that omitted a material litigation and write the one fact that would move regulatory approval is a for integration-risk PMO.

RECOMMENDATION Choose Regulatory approval is a timing risk / A deal risk on this M&A Due Diligence / Earnings and Revenue Quality packet (regulatory-approval critical-path calendar after a CIM that omitted a material litigation). Lead with the M&A Due Diligence option regulatory-approval critical-path calendar can support after a CIM that omitted a material litigation, then the two facts that force it, then the Monday action for integration-risk PMO in a sponsor doing confirmatory after a tight auction.

COMMAND RETURNS - Bottom-line M&A Due Diligence option on regulatory approval is a, then the evidence in regulatory-approval critical-path calendar, then the action for integration-risk PMO - Hypothesis scorecard against regulatory-approval critical-path calendar: supported / rejected / untestable - Regulatory or exam hook Earnings and Revenue Quality would cite - Earnings and Revenue Quality finding in regulatory-approval critical-path calendar that a second reviewer can re-perform